Key statistics
As of last trade Exelixis Inc (EX9:FRA) traded at 24.03, -2.40% below its 52-week high of 24.62, set on Aug 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.03 |
---|---|
High | 24.03 |
Low | 24.03 |
Bid | 24.14 |
Offer | 24.39 |
Previous close | 23.55 |
Average volume | 99.00 |
---|---|
Shares outstanding | 285.25m |
Free float | 280.35m |
P/E (TTM) | 22.83 |
Market cap | 7.60bn USD |
EPS (TTM) | 1.17 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:22 BST.
More ▼
Press releases
- Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
- Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
- Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors
- Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
- Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
More ▼